Pharma Industry Reputation: What Is At Stake With COVID-19?
The massive need for a COVID-19 vaccine and treatments has heightened the biopharmaceutical industry’s visibility among consumers and the world’s largest biopharma companies are getting a boost in positive perception this year, according to a new FutureBrand survey. If sustained, this could have dividends in areas such as attracting industry talent and clinical trial participants. But much remains to be seen as biopharma navigates the final stretch of clinical development, regulatory review, distribution and patient access.
You may also be interested in...
Pharma Not-For-Profit Projects Can Only Improve Reputation
Sanofi is the latest drugmaker to announce a major initiative aimed at improving access to medicines in poorer countries, the type of move that should continue to lift the reputation of big pharma above the likes of big oil and big tobacco.
Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity
The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.
Kodak Deal On Hold Until Allegations Cleared
A major $765m loan agreed by the US International Development Finance Corporation to allow Kodak to establish a pharmaceuticals unit has been put on hold until allegations of wrongdoing are resolved, as rumors swirl about insider trading.